A Randomized, Sponsor-Open, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of RO7062931 With Single Ascending Doses in Healthy Volunteers and Multiple Doses and Modified Regimens in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection
Phase of Trial: Phase I
Latest Information Update: 27 Aug 2018
At a glance
- Drugs RO 7062931 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 20 Aug 2018 Planned End Date changed from 7 May 2019 to 25 Apr 2019.
- 20 Aug 2018 Planned primary completion date changed from 7 May 2019 to 25 Apr 2019.
- 17 Jul 2018 Planned End Date changed from 21 May 2019 to 7 May 2019.